Dose–response relationships of psilocybin-induced subjective experiences in humans
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Background: Psilocybin is the psychoactive component in Psilocybe mushrooms (‘magic mushrooms’). Whether and how the quality of the psilocybin-induced experience might mediate beneficial health outcomes is currently under investigation, for example, in therapeutic applications. However, to date, no meta-analysis has investigated the dose-dependency of subjective experiences across available studies. Aim: Establishing dose–response relationships of the subjective experiences induced by psilocybin in healthy study participants and a comparison of patient groups. Method: We applied a linear meta-regression approach, based on the robust variance estimation framework, to obtain linear dose–response relationship estimates on questionnaire ratings after oral psilocybin administration. Data were obtained from the Altered States Database, which contains data extracted from MEDLINE-listed journal articles that used standardized and validated questionnaires: the Altered States of Consciousness Rating Scale, the Mystical Experience Questionnaire and the Hallucinogen Rating Scale. Results: Psilocybin dose positively correlated with ratings on most factors and scales, mainly those referring to perceptual alterations and positively experienced ego dissolution. Measures referring to challenging experiences exhibited small effects and were barely modulated by dose. Conclusion: Psilocybin intensified almost all characteristics of altered states of consciousness assessed with the given questionnaires. Because subjective experiences are not only determined by dose, but also by individual and environmental factors, the results may only apply to controlled laboratory experiments and not to recreational use. This paper may serve as a general literature citation for the use of psilocybin in experimental and clinical research, to compare expected and observed subjective experiences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 9×
“…2015), the sensitivity analyses produced robust effect size estimates for different values of p. Additional meta-analysis including patient data In the additional analysis, we included the available patient data on the 5D-ASC (Bogenschutz et al., 2015; Griffiths et al., 2016; Grob et al., 2011;)”
BackgroundMethodResultInfluentialRobust variance estimation in meta‐regression with dependent effect size estimates
Hedges, L. V., Tipton, E., & Johnson, M. C. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.5 · Cited by 2,086 · cited 3×
“A recently presented meta-analytical approach, the robust variance estimation (RVE) framework (Hedges et al., 2010; Tipton, 2015), permits the inclusion of small samples and statistically dependent effect sizes to determine reliable dose–response estimates.”
MethodBasics of meta‐analysis: I 2 is not an absolute measure of heterogeneity
Borenstein, M., Higgins, J. P. T., Hedges, L. V., & Rothstein, H. R. (2017) · Research Synthesis Methods · doi:10.1002/jrsm.1230 · Cited by 1,848 · cited 4×
“…across studies, I², represents the proportion of the observed variance that is due to systematic differences between studies rather than random error, for example, resulting from differences in study population, study design or bias (Borenstein et al., 2017; Higgins and Thompson, 2002).”
MethodResultInfluentialAnalysing Data and Undertaking Meta‐Analyses
Deeks, J. J., Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch9 · Cited by 1,800
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 4×
“…reporting data on patients with cancer-related psychiatric distress (Ross et al., 2016), one study reporting data on patients with major depressive disorder (Davis et al., 2020) and two studies reporting data on patients with treatment-resistant major depression (Carhart-Harris et al., 2016, 2018).”
BackgroundResultInfluential
Cited by
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O’Keane, V., Peck, S. K., Simmons, H., Sisa, C., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01648-7 · Cited by 187
“The 5D-ASC outcome in the present study is also consistent with a meta-analysis of studies of psilocybin in healthy volunteers and COMP 001 where participants with TRD were withdrawn from antidepressant drugs [5, 49].”
BackgroundResultPerez, N., Langlest, F., Mallet, L., De Pieri, M., Sentissi, O., Thorens, G., Seragnoli, F., Zullino, D., Kirschner, M., Kaiser, S., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.07.011 · Cited by 88
“…of anxiety ( Carhart-Harris et al., 2016 ), and the very nature of psychedelics trips with dose-dependent effect for ego dissolution that can be associated with a sense of loss of control with subsequent levels of anxiety or even short-term psychosis-like symptoms ( Hirschfeld and Schmidt, 2021 ).”
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“A precise mechanistic understanding of psychedelics is challenging because of the synergistic action of pharmacotherapy and psychotherapy, together with the induction of a wide range of complex subjective experiences with marked individual variation (19).”
BackgroundEvens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
Systematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36
Metadata
- Authors
- Hirschfeld, T., & Schmidt, T. T.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-03-04
- Volume
- 35
- Issue
- 4
- Pages
- 384-397
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3135335789
- Cited by
- 93
- References
- 56
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose–response relationships of psilocybin-induced subjective experiences in humans. https://app.cochat.ai/papers/10.1177/0269881121992676
- The paper
- Hirschfeld, T., & Schmidt, T. T. (2021). Dose–response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology. https://doi.org/10.1177/0269881121992676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.